Skip to content

Clinical Study on the Relief of Constipation by Pediococcus acidilactici PA53

Clinical Study on the Relief of Constipation by Pediococcus acidilactici PA53

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126130
Enrollment
Unknown
Registered
2026-06-04
Start date
2025-02-28
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipated patients (having fewer than 3 bowel movements per week and/or Bristol Stool Scale types 1 and 2)

Interventions

Placebo group:Administer oral placebo
Probiotics Group:Administer orally a powder containing Pediococcus acidilactici PA53.

Sponsors

General Hospital of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with constipation (defecation frequency less than 3 times per week and/or Bristol Stool Scale type 1 and 2); 2. Patients who have signed the informed consent form; 3. Patients capable of completing the study in accordance with the trial protocol requirements; 4. Patients (including male patients) have no plans for pregnancy from 14 days prior to screening until 6 months after the trial and voluntarily adopt effective contraceptive measures.

Exclusion criteria

Exclusion criteria: 1. Individuals who have consumed food or medications with functions similar to those being tested within a short period, which may affect the judgment of results; 2. Individuals who alter their dietary patterns during the study period; 3. Individuals with severe allergies or immunodeficiency; 4. Females who are pregnant, breastfeeding, or planning to become pregnant; 5. Individuals with severe diseases of vital organs (e.g., cardiovascular, pulmonary, hepatic, or renal systems), diabetes, severe metabolic disorders (e.g., thyroid diseases), malignant tumors, or severe immune system disorders; 6. Individuals who have used antibiotics within the past two weeks; 7. Individuals with severe psychological or mental disorders; 8. Other individuals deemed unsuitable for participation by the investigators.

Design outcomes

Primary

MeasureTime frame
Improvement of constipation symptoms;

Secondary

MeasureTime frame
Quality of life and psychological status;Gastrointestinal functional biochemical markers;Gut hormones;Inflammatory and immune markers;Gut microbiota;

Countries

China

Contacts

Public ContactXia Yuhhan

General Hospital of Ningxia Medical University

xyhleo@163.com+86 951 6743028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026